$GBT

Global Blood Therapeutics Inc.

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$33 ▲0.61%

Extented Hours

VOLUME

1,247,896

DAY RANGE

31.49 - 33.76

52 WEEK

21.65 - 40.69

Join Discuss about GBT with like-minded investors

profile
@dros #droscrew
recently

+Initiations 3/28: $ALBO $ASND $BBAI $BEP $BTCS $DRCT $GBT $GMED $HTZ NUVA $OBSV $ONCR $RBLX $SPIR $TCB $TCN $U

144 Replies 11 👍 7 🔥

profile
@dros #droscrew
recently

Downgrades 1/20: $ACI $AMCR $AMH $BE $BPMP $BYND $CAT $CRNT $CX $ELF $GBT $GGB $GRTS $GSK $HTA $IFS $INVH $KNOP $KR $MIK $NVO $OI $OLLI $PTVE $RDFN $RUN $RYAAY $SENS $SHLX $SNAP $SWAV $UDR $XHR

88 Replies 11 👍 10 🔥

profile
@Troydeen29 #FOREX
recently

goodnight everyone. I will try to sleep soon and will start my trading tomorrow 9am GBT precisely ;)

121 Replies 11 👍 12 🔥

profile
@ivtrades-Chris #ivtrades
recently

$GBT almost halved

42 Replies 15 👍 13 🔥

profile
@dros #droscrew
recently

yeah GBT picking up nicely matt

127 Replies 15 👍 9 🔥

profile
@RedSunCap #droscrew
recently

GBT looking like fire

66 Replies 12 👍 10 🔥

Key Metrics

Market Cap

2.14 B

Beta

1.23

Avg. Volume

2 M

Shares Outstanding

65.10 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-02

Next Dividend Date

Company Information

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

CEO: Ted Love

Website:

HQ: 181 Oyster Point Blvd South San Francisco, 94080 California

Related News